Anxiety DisordersPsilocybin

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

This double-blind, randomised study (n=18) investigated the effects of psilocybin at different dosages. It found that positive effects were most pronounced at 20/30mg per 70kg. At two and 14 months later, participants indicated positive changes and rated the experience as one of the top 5 life experiences.

Authors

  • Roland Griffiths
  • Matthew Johnson
  • William Richards

Published

Psychopharmacology
individual Study

Abstract

Objectives

This double-blind study evaluated psilocybin (0, 5, 10, 20, 30 mg/70 kg, p.o.) administered under supportive conditions.

Methods

Participants were 18 adults (17 hallucinogen-naïve). Five 8-hour sessions were conducted individually for each participant at 1-month intervals. Participants were randomized to receive the four active doses in either ascending or descending order (9 participants each). Placebo was scheduled quasi-randomly. During sessions volunteers used eyeshades and were instructed to direct their attention inward. Volunteers completed questionnaires assessing effects immediately after and 1 month after each session, and at 14 months follow-up.

Results

Psilocybin produced acute perceptual and subjective effects including, at 20 and/or 30 mg/70 kg, extreme anxiety/fear (39% of volunteers) and/or mystical-type experience (72% of volunteers). One month after sessions at the two highest doses, volunteers rated the psilocybin experience as having substantial personal and spiritual significance, and attributed to the experience sustained positive changes in attitudes, mood, and behavior, with the ascending dose sequence showing greater positive effects. At 14 months, ratings were undiminished and were consistent with changes rated by community observers. Both the acute and persisting effects of psilocybin were generally a monotonically increasing function of dose, with the lowest dose showing significant effects.

Conclusions

Under supportive conditions, 20 and 30 mg/70 kg psilocybin occasioned mystical-type experiences having persisting positive effects on attitudes, mood and behavior. Implications for therapeutic trials are discussed.

Available with Blossom Pro

Research Summary of 'Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects'

Introduction

Psilocybin is the principal psychoactive compound in Psilocybe mushrooms and, like other classic hallucinogens, acts primarily at 5-HT2A receptors to produce robust alterations in perception, cognition, affect and bodily sensation. Earlier clinical work found that subjective reactions to psilocybin ranged from positive to negative, and that intensely valued personal or mystical-type experiences were uncommon in many early studies. Subsequent research that used higher doses together with more preparation and interpersonal support reported higher rates of positively valenced, sometimes mystical, experiences that participants rated as personally significant and enduring. This study by Griffiths and colleagues aimed to characterise dose-related acute and persisting psychological effects of a range of psilocybin doses (0, 5, 10, 20, 30 mg/70 kg) administered under supportive, laboratory conditions. The investigators used a double-blind, crossover design with five 8-hour sessions per participant and compared ascending versus descending sequences of active dose exposure, with outcome assessments immediately after sessions, at 1 month, and at a 14-month follow-up. The study sought to define both the likelihood of mystical-type experiences across doses and the durability and nature of any persisting changes in attitudes, mood, behaviour and spirituality.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (8)

Papers cited by this study that are also in Blossom

The psychopharmacology of hallucinogens

Abraham, H. D., Aldridge, A. M., Gogia, P. · Neuropsychopharmacology (1996)

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)

Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Reactions to psilocybin administered in a supportive environment

Leary, T., Litwin, G. H., Metzner, R. · Journal of Nervous and Mental Disease (1977)

LSD-assisted psychotherapy and the human encounter with death

Goodman, L. E., Grof, S., Kurland, A. A. et al. · Journal of Transpersonal Psychology (1972)

Experimental Psychiatry. V - Psilocybine, a New Psychotogenic Drug

Rinkel, M., Atwell, C. R., DiMascio, A. et al. · New England Journal of Medicine (1960)

Cited By (270)

Papers in Blossom that reference this study

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial

Mertens, L. J., Koslowski, M., Betzler, F. et al. · JAMA Psychiatry (2026)

Age moderates the relationship between psychedelics use and mental health in naturalistic settings

Gregorio, G. D., Basset, S., Manmohan, H. et al. · Research Square (2026)

Pilot study of psilocybin in patients with post-treatment lyme disease

Garcia-Romeu, A., Naudé, G. P., Rebman, A. W. et al. · Scientific Reports (2026)

Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions

Griffiths, R. R., Jesse, R., Richards, W. A. et al. · Psychedelic Medicine (2026)

12 cited
An open-label pilot study of psilocybin-assisted therapy for binge eating disorder

Dallery, J., Miller, J. L., Boissoneault, J. et al. · Journal of Eating Disorders (2026)

Show all 270 papers
Intact neurophysiological markers of death denial in long-term ayahuasca users

Dor-Ziderman, Y., David, J., Berkovich-Ohana, A. · Psychopharmacology (2025)

Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre-Administration in a Randomized, Double-Blind, Cross-Over Phase I Trial

Becker, A. M., Humbert-Droz, M., Mueller, L. et al. · Clinical Pharmacology and Therapeutics (2025)

Acute psilocybin and ketanserin effects on cerebral blood flow: 5-HT2AR neuromodulation in healthy humans

Larsen, K., Lindberg, U., Ozenne, B. et al. · Journal of Cerebral Blood Flow and Metabolism (2025)

A qualitative analysis of the psychedelic mushroom come-up and come-down

Brouwer, A., Brown, J., Erowid, E. et al. · npj Mental Health Research (2025)

From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS)

Zeifman, R. J., Spriggs, M. J., Kettner, H. et al. · Scientific Reports (2025)

24 cited
Clinically relevant acute subjective effects of psychedelics beyond mystical experience

Yaden, D. B., Goldy, S. P., Weiss, B. et al. · Nature Reviews Psychology (2024)

LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up

Holze, F., Gasser, P., Müller, F. et al. · BJPsych Open (2024)

26 cited
How Do Psychedelics Reduce Fear of Death?

Letheby, C. · Neuroethics (2024)

11 cited
Psychedelic Experiences Increase Mind Perception but do not Change Atheist-Believer Status: A Prospective Longitudinal Study

Nayak, S., Jackson, H., Griffiths, R. R. et al. · Journal of Psychoactive Drugs (2024)

Treatment with psychedelics is psychotherapy: beyond reductionism

Gründer, G., Brand, M., Mertens, L. J. et al. · Lancet Psychiatry (2024)

Subjective long-term emotional and social effects of recreational MDMA use: the role of setting and intentions

Elmer, T., Vannoy, T. K., Studerus, E. et al. · Scientific Reports (2024)

10 cited
Effects of DMT on mental health outcomes in healthy volunteers

Timmermann, C., Zeifman, R. J., Erritzoe, D. et al. · Scientific Reports (2024)

29 cited
Safety pharmacology of acute psilocybin administration in healthy participants

Straumann, I., Holze, F., Becker, A. M. et al. · Neuroscience Applied (2024)

15 cited
Perceptions of psychedelic personality change, determinants of use, setting and drug moderation: Toward a holistic model

Weiss, B., Sleep, C., Beller, N. et al. · Journal of Psychedelic Studies (2023)

10 cited
Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study

Mason, N. L., Szabo, A., Kuypers, K. P. C. et al. · Brain Behavior and Immunity - Health (2023)

Cellular rules underlying psychedelic control of prefrontal pyramidal neurons

Ekins, T. G., Brooks, I., Kailasa, S. et al. · Biorxiv (2023)

Case analysis of long-term negative psychological responses to psychedelics

Bremler, R., Katati, N., Shergill, P. et al. · Scientific Reports (2023)

History repeating: guidelines to address common problems in psychedelic science

Van Elk, M., Fried, E. I. · Therapeutic Advances in Psychopharmacology (2023)

94 cited
Learned Helplessness As a Potential Transdiagnostic Therapeutic Mechanism of Classic Psychedelics

Tiwari, P., Sayali, C., Doss, M. K. et al. · Psychedelic Medicine (2023)

Psychedelic therapy in the treatment of addiction: the past, present and future

Zafar, R., Siegel, M., Harding, R. et al. · Frontiers in Psychiatry (2023)

Assessment of the acute effects of 2C-B vs psilocybin on subjective experience, mood and cognition

Mallaroni, P., Mason, N. L., Reckweg, J. T. et al. · Clinical Pharmacology and Therapeutics (2023)

39 cited
Effect of LSD and music on the time-varying brain dynamics

Adamska, I., Finc, K. · Psychopharmacology (2023)

7 cited
Meditation Trips: A Thematic Analysis of the Combined Naturalistic Use of Psychedelics With Meditation Practices

Azmoodeh, K., Thomas, E., Kamboj, S. K. · Experimental and Clinical Psychopharmacology (2023)

9 cited
Transpersonal Ecodelia: Surveying Psychedelically Induced Biophilia

Luke, D., Gandy, S., Irvine, A. et al. · Psychoactives (2023)

17 cited
Case report: Prolonged amelioration of mild red-green color vision deficiency following psilocybin mushroom use

Barnett, B. S., Sweat, N. W., Hendricks, P. S. · Drug Science Policy and Law (2023)

4 cited
Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020

Kopra, E., Ferris, J. A., Winstock, A. R. et al. · Journal of Psychopharmacology (2023)

Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms

Nikolaidis, A., Lancelotta, R., Gukasyan, N. et al. · Journal of Affective Disorders (2023)

Psychedelics and psychological strengths

Brasher, T., Rosen, D., Spinella, M. · International Journal of Wellbeing (2023)

Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation

Modlin, N. L., Miller, T. M., Rucker, J. J. et al. · Journal of Affective Disorders (2023)

The association between naturalistic use of psychedelics and co-occurring substance use disorders

Rabinowitz, J., Lev-Ran, S., Gross, R. · Frontiers in Psychiatry (2023)

Altered States of Consciousness During Ceremonial San Pedro Use

Bohn, A., Kiggen, M. H. H., Uthaug, M. V. et al. · International Journal for the Psychology of Religion (2022)

Therapeutic use of psilocybin: Practical considerations for dosing and administration

MacCallum, C. A., Pistawka, C. A., Deol, J. K. et al. · Frontiers in Psychiatry (2022)

The Altered States Database: Psychometric data from a systematic literature review

Prugger, J., Derdiyok, E., Dinkelacker, J. et al. · Scientific Data (2022)

Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials

Herrmann, Z., Earleywine, M., De Leo, J. et al. · Journal of Psychoactive Drugs (2022)

Neural Mechanisms and Psychology of Psychedelic Ego Dissolution

Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)

Pharmacological, Neural, and Psychological Mechanisms underlying Psychedelics: A Critical Review

van Elk, M., Yaden, D. B. · Neuroscience and Biobehavioral Reviews (2022)

Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees

Kiraga, M. K., Kuypers, K. P. C., Uthaug, M. V. et al. · Frontiers in Psychiatry (2022)

20 cited
Belief changes associated with psychedelic use

Nayak, S., Singh, M., Yaden, D. B. et al. · Journal of Psychopharmacology (2022)

Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study

Hartong, V., van Emmerik, A. · Journal of Psychoactive Drugs (2022)

Group VR experiences can produce ego attenuation and connectedness comparable to psychedelics

Glowacki, D. R., Wonnacott, M. D., Freire, R. et al. · Scientific Reports (2022)

31 cited
Psychedelic Therapy for Body Dysmorphic Disorder

Johnson, S., Letheby, C. · Journal of Psychedelic Studies (2022)

The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences

Whitney, S., Yaden, D. B., Lipson, J. et al. · Frontiers in Psychology (2022)

Psychedelic Resting-state Neuroimaging: A Review and Perspective on Balancing Replication and Novel Analyses

McCulloch, D. E-W., Knudsen, G. M., Barrett, F. S. et al. · Neuroscience and Biobehavioral Reviews (2022)

Psilocybin-Assisted Compassion Focused Therapy for Depression

Pots, W., Chakhssi, F. · Frontiers in Psychology (2022)

Magic Mushroom Use: A Qualitative Interview Study of Post-Trip Impacts and Strategies for Optimizing Experiences

Shaw, L., Rea, K., Lachowsky, N. J. et al. · Journal of Psychoactive Drugs (2022)

11 cited
Predictors and potentiators of psychedelic-occasioned mystical experiences

Gandy, S. · Journal of Psychedelic Studies (2022)

Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report

McCulloch, D. E-W., Madsen, M. K., Jensen, P. S. et al. · Frontiers in Pharmacology (2022)

79 cited
Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil

Maia, L. O., Massarentti, C. M., Tófoli, L.F. · Psychopharmacology (2022)

28 cited
Neural Plasticity in the Ventral Tegmental Area, Aversive Motivation during Drug Withdrawal and Hallucinogenic Therapy

Vargas-Perez, H., Grieder, T. E., Van Der Kooy, D. · Journal of Psychoactive Drugs (2022)

Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting

Argento, E., Socias, M. E., Hayashi, K. et al. · International Journal of Drug Policy (2022)

Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder

Markopoulos, A., Inserra, A., De Gregorio, D. et al. · Frontiers in Pharmacology (2022)

30 cited
Classic Psychedelic Drugs: Update on Biological Mechanisms

Vollenweider, F. X., Smallridge, J. W. · Pharmacopsychiatry (2022)

71 cited
Human behavioral pharmacology of psychedelics

Strickland, J. C., Johnson, M. W. · Advances in Pharmacology (2022)

5 cited
Models of psychedelic drug action: modulation of cortical-subcortical circuits

Doss, M. K., Madden, M. B., Gaddis, A. et al. · Brain (2021)

Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs

Yaden, D. B., Berghella, A. P., Regier, P. S. et al. · International Journal of Drug Policy (2021)

41 cited
Ketamine as a Treatment for Anorexia Nervosa: A Narrative Review

Keeler, J. L., Treasure, J., Juruena, M. F. et al. · Nutrients (2021)

Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey

Kuc, J., Kettner, H., Rosas, F. E. et al. · Psychopharmacology (2021)

Day trip to hell: A mixed methods study of challenging psychedelic experiences

Johnstad, P. G. · Journal of Psychedelic Studies (2021)

43 cited
Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis

Yang, F., Yang, S., Tseng, P. et al. · Psychiatry Investigation (2021)

Persisting effects of ayahuasca on empathy, creative thinking, decentering, personality, and well-being

Kiraga, M. K., Mason, N. L., Uthaug, M. V. et al. · Frontiers in Pharmacology (2021)

56 cited
Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy

Johnson, M. W., Gründer, G., Betzler, F. et al. · Current Addiction Reports (2021)

Psychedelics, sociality, and human evolution

Rodríguez Arce, J. M., Winkelman, M. J. · Frontiers in Psychology (2021)

Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience

Madsen, M. K., Stenbaek, D. S., Arvidsson, A. et al. · European Neuropsychopharmacology (2021)

Does psychedelic therapy have a transdiagnostic action and prophylactic potential?

Kočárová, C., Horacek, J., Carhart-Harris, R. L. · Frontiers in Psychiatry (2021)

73 cited
The chemical induction of synaesthesia

Luke, D., Lungu, L., Friday, R. et al. · Human Psychopharmacology (2021)

Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa

Rodan, S., Aouad, P., McGregor, I. S. et al. · OBM Neurobiology (2021)

Psychedelic medicalization, public discourse, and the morality of ego dissolution

Gearin, A. K., Devenot, N. · International Journal of Cultural Studies (2021)

Catalysts for change: the cellular neurobiology of psychedelics

Bement, W., Banks, M. I., Zahid, Z. et al. · Molecular Biology of the Cell (2021)

31 cited
Psychedelics and health behaviour change

Teixeira, P. J., Johnson, M. W., Timmermann, C. et al. · Journal of Psychopharmacology (2021)

The Potential Role of Psychedelic Drugs in Mental Health Care of the Future

Gründer, G., Jungaberle, H., Gründer, G. · Pharmacopsychiatry (2021)

Set and Setting in the Santo Daime

Hartogsohn, I. · Frontiers in Pharmacology (2021)

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)

1015 cited
Examining changes in personality following shamanic ceremonial use of ayahuasca

Weiss, B., Miller, J. D., Carter, N. T. et al. · Scientific Reports (2021)

53 cited
Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes

Agin-Liebes, G. I., Lancelotta, R., Uthaug, M. V. et al. · ACS Pharmacology and Translational Science (2021)

Baseline power of theta oscillations predicts mystical-type experiences induced by DMT in a natural setting

Tagliazucchi, E., Zamberlan, F., Cavanna, F. et al. · Frontiers in Psychiatry (2021)

Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects

Aday, J. S., Davis, A. K., Mitzkovitz, C. M. et al. · ACS Pharmacology and Translational Science (2021)

Neural and subjective effects of inhaled N,N-dimethyltryptamine in natural settings

Pallavicini, C., Cavanna, F., Zamberlan, F. et al. · Journal of Psychopharmacology (2021)

75 cited
Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals

McCulloch, D. E-W., Madsen, M. K., Stenbæk, D. S. et al. · Journal of Psychopharmacology (2021)

Narratives of the mystical among users of psychedelics

Pedersen, W., Copes, H., Gashi, L. · Acta Sociologica (2021)

Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences

Gashi, L., Sandberg, S., Pedersen, W. · International Journal of Drug Policy (2021)

Entheogenic Experience and Spirituality

Johnstad, P. G. · Method and Theory in the Study of Religion (2020)

The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects

Yaden, D. B., Griffiths, R. R. · ACS Pharmacology and Translational Science (2020)

People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences

Williams, T. M., Davis, A. K., Xin, Y. et al. · Drugs Education Prevention and Policy (2020)

Psychedelics and Psychotherapy

Nayak, S., Johnson, M. W. · Pharmacopsychiatry (2020)

The History of Psychedelics in Psychiatry

Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)

The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health

Gandy, S., Forstmann, M., Carhart-Harris, R. L. et al. · Health Psychology Open (2020)

Acute subjective effects in LSD- and MDMA-assisted psychotherapy

Schmid, Y., Gasser, P., Oehen, P. et al. · Journal of Psychopharmacology (2020)

72 cited
The therapeutic potential of microdosing psychedelics in depression

Kuypers, K. P. C. · Therapeutic Advances in Psychopharmacology (2020)

Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland

Kangaslampi, S., Hausen, A., Rauteenmaa, T. · Journal of Psychoactive Drugs (2020)

Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments

Greenway, K. T., Garel, N., Jerome, L. et al. · Expert Review of Clinical Pharmacology (2020)

Isness: Using Multi-Person VR to Design Peak Mystical Type Experiences Comparable to Psychedelics

Glowacki, D. R., Wonnacott, M. D., Freire, R. et al. · Association for Computing Machinery (2020)

32 cited
Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications

O'callaghan, C., Hubik, D. J., Psychiatry, M. et al. · Journal of Music Therapy (2020)

Long-term effects of psychedelic drugs: A systematic review

Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K. et al. · Neuroscience and Biobehavioral Reviews (2020)

Reviewing the potential of psychedelics for the treatment of PTSD

Krediet, E., Bostoen, T., Breeksema, J. J. et al. · International Journal of Neuropsychopharmacology (2020)

Tripping on nothing: placebo psychedelics and contextual factors

Olson, J. A., Suissa-Rocheleau, L., Lifshitz, M. et al. · Psychopharmacology (2020)

Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance

Wolff, M., Evens, R., Mertens, L. J. et al. · Frontiers in Psychiatry (2020)

Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience

Lewis, C. R., Preller, K. H., Braden, B. B. et al. · Biomedicines (2020)

24 cited
Emotions and brain function are altered up to one month after a single high dose of psilocybin

Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)

Acute effects of psilocybin on glutamate concentration levels, functional connectivity and subjective state

Mason, N. L., Feilding, A., Ramaekers, J. G. · European Neuropsychopharmacology (2020)

Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey

Garcia-Romeu, A., Davis, A. K., Griffiths, R. R. et al. · Frontiers in Psychiatry (2020)

121 cited
Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials

Fuentes, J. J., Fonseca, F., Elices, M. et al. · Frontiers in Psychiatry (2020)

Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety

Davis, A. K., Barrett, F. S., Griffiths, R. R. · Journal of Contextual Behavioral Science (2020)

From Egoism to Ecoism: Psychedelics Increase Nature Relatedness in a State-Mediated and Context-Dependent Manner

Kettner, H., Gandy, S., Haijen, E. C. H. M. et al. · International Journal of Environmental Research and Public Health (2019)

131 cited
Modulation of Social Cognition via Hallucinogens and “Entactogens”.

Preller, K. H., Vollenweider, F. X. · Frontiers in Psychiatry (2019)

Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat

Smigielski, L., Kometer, M., Scheidegger, M. et al. · Scientific Reports (2019)

126 cited
Toward a contextual psychedelic-assisted therapy: Perspectives from Acceptance and Commitment Therapy and contextual behavioral science

Luoma, J. B., Sabucedo, P., Eriksson, J. et al. · Journal of Contextual Behavioral Science (2019)

Psychedelic microdosing benefits and challenges: an empirical codebook

Anderson, T., Petranker, R., Christopher, A. et al. · Harm Reduction Journal (2019)

Replication and extension of a model predicting response to psilocybin

Russ, S. L., Carhart-Harris, R. L., Maruyama, G. et al. · Psychopharmacology (2019)

55 cited
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function

Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)

5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety

Davis, A. K., So, S., Lancelotta, R. et al. · The American Journal of Drug and Alcohol Abuse (2019)

113 cited
States and traits related to the quality and consequences of psychedelic experiences

Russ, S. L., Carhart-Harris, R. L., Maruyama, G. et al. · Psychology of Consciousness Theory Research and Practice (2019)

Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being

Mason, N. L., Mischler, E., Uthaug, M. V. et al. · Journal of Psychoactive Drugs (2019)

136 cited
Long-lasting analgesic effect of the psychedelic drug changa: A case report

Ona, G., Troncoso, S. · Journal of Psychedelic Studies (2019)

A systematic study of microdosing psychedelics

Polito, V., Stevenson, R. J. · PLOS ONE (2019)

197 cited
Trait Openness and serotonin 2A receptors in healthy volunteers: A positron emission tomography study

Stenbæk, D. S., Kristiansen, S., Burmester, D. et al. · Human Brain Mapping (2019)

9 cited
Microdosing psychedelics: personality, mental health, and creativity differences in microdosers

Anderson, T., Petranker, R., Rosenbaum, D. et al. · Psychopharmacology (2019)

142 cited
Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study

Barsuglia, J. P., Davis, A. K., Palmer, R. et al. · Frontiers in Psychology (2018)

Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions

Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)

Predicting responses to psychedelics: a prospective study

Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)

339 cited
Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression

Roseman, L., Demetriou, L., Wall, M. B. et al. · Neuropharmacology (2018)

49 cited
143 cited
Psychedelics and music: neuroscience and therapeutic implications

Barrett, F. S., Preller, K. H., Kaelen, M. · International Review of Psychiatry (2018)

DMT models the near-death experience

Timmermann, C., Roseman, L., Williams, L. et al. · Frontiers in Psychology (2018)

Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition

Barrett, F. S., Carbonaro, T. M., Hurwitz, E. et al. · Psychopharmacology (2018)

78 cited
A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification

Davis, A. K., Renn, E., Windham-Herman, A. M. et al. · Journal of Psychoactive Drugs (2018)

Positive psychology in the investigation of psychedelics and entactogens: A critical review

Jungaberle, H., Thal, S., Zeuch, A. et al. · Neuropharmacology (2018)

DARK Classics in Chemical Neuroscience: Psilocybin

Geiger, H. A., Wurst, M. G., Daniels, R. N. · ACS Chemical Neuroscience (2018)

Psychedelics promote structural and functional neural plasticity

Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

Johnson, M. W., Griffiths, R. R., Hendricks, P. S. et al. · Neuropharmacology (2018)

Psychological variables implied in the therapeutic effect of ayahuasca: A contextual approach

Franquesa, A., Sainz-Cort, A., Gandy, S. et al. · Psychiatry Research (2018)

47 cited
Integrating Psychedelic Medicines and Psychiatry: Theory and Methods of a Model Clinic

Sloshower, J. A. · Plant Medicines Healing and Psychedelic Science (2018)

The Use of Salvia divinorum from a Mazatec Perspective

Maqueda, A. E. · Plant Medicines Healing and Psychedelic Science (2018)

Unifying theories of psychedelic drug effects

Swanson, L. R. · Frontiers in Pharmacology (2018)

Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics

Schindler, E. A. D., Wallace, R. M., Sloshower, J. A. et al. · Frontiers in Pharmacology (2018)

Serotonergic psychedelics and personality: A systematic review of contemporary research

Bouso, J. C., Dos Santos, R. G., Hallak, J. E. · Neuroscience and Biobehavioral Reviews (2018)

The hidden therapist: evidence for a central role of music in psychedelic therapy

Kaelen, M., Giribaldi, B., Raine, J. et al. · Psychopharmacology (2018)

213 cited
LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation

Sumiyoshi, T., Kraehenmann, R., Pokorny, D. et al. · Frontiers in Pharmacology (2017)

Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms

Carhart-Harris, R. L., Roseman, L., Bolstridge, M. et al. · Scientific Reports (2017)

Neuroticism is associated with challenging experiences with psilocybin mushrooms

Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Personality and Individual Differences (2017)

78 cited
Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow

Lewis, C. R., Preller, K. H., Kraehenmann, R. et al. · NeuroImage (2017)

74 cited
Serotonin 2A receptor signaling underlies LSD-induced alteration of the neural response to dynamic changes in music

Barrett, F. S., Preller, K. H., Herdener, M. et al. · Cerebral Cortex (2017)

Psychedelic Drugs in Biomedicine

Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R. et al. · Trends in Pharmacological Sciences (2017)

Long-lasting subjective effects of LSD in normal subjects

Schmid, Y., Liechti, M. E. · Psychopharmacology (2017)

Psychedelic pleasures: An affective understanding of the joys of tripping

Bøhling, F. · International Journal of Drug Policy (2017)

MDMA-Induced Dissociative State not Mediated by the 5-HT2A Receptor

Kuypers, K. P. C., Puxty, D. J., Ramaekers, J. G. et al. · Frontiers in Pharmacology (2017)

Effects of LSD on music-evoked brain activity

Kaelen, M., Lorenz, R., Barrett, F. S. et al. · Biorxiv (2017)

Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress

Swift, T. C., Belser, A. B., Agin-Liebes, G. et al. · Journal of Humanistic Psychology (2017)

130 cited
Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis

Belser, A. B., Agin-Liebes, G. I., Swift, T. C. et al. · Journal of Humanistic Psychology (2017)

Modern clinical research on LSD

Liechti, M. E. · Neuropsychopharmacology (2017)

Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults

Brown, R. T., Nicholas, C. R., Cozzi, N. V. et al. · Clinical Pharmacokinetics (2017)

The fibrinolytic system: A new target for treatment of depression with psychedelics

Idell, R. D., Florova, G., Komissarov, A. A. et al. · Medical Hypotheses (2017)

The Effects of Hallucinogens on Gene Expression

Martin, D. A., Nichols, C. D., Nichols, Á. C. D. · Current Topics in Behavioral Neurosciences (2017)

Phenomenology, Structure, and Dynamic of Psychedelic States

Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)

Classical hallucinogens and neuroimaging: A systematic review of human studies: hallucinogens and neuroimaging

Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · Neuroscience and Biobehavioral Reviews (2016)

The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens

Canal, C. E., Murnane, K. S. · Journal of Psychopharmacology (2016)

Alterations of consciousness and mystical-type experiences after acute LSD in humans

Liechti, M. E., Dolder, P. C., Schmid, Y. · Psychopharmacology (2016)

190 cited
Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences

Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)

Clinical Applications of Hallucinogens: A Review

Garcia-Romeu, A., Kersgaard, B., Addy, P. H. · Experimental and Clinical Psychopharmacology (2016)

174 cited
Long-term follow-up of psilocybin-facilitated smoking cessation

Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)

562 cited
Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI)

Nour, M. R., Evans, J., Nutt, D. J. et al. · Frontiers in Human Neuroscience (2016)

LSD acutely impairs fear recognition and enhances emotional empathy and sociality

Dolder, P. C., Schmid, Y., Müller, F. et al. · Neuropsychopharmacology (2016)

Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans

Nunes, A. A., Dos Santos, R. G., Osório, F. L. et al. · Journal of Psychoactive Drugs (2016)

80 cited
Psychedelics

Nichols, D. E. · Pharmacological Reviews (2016)

The therapeutic potentials of ayahuasca: possible effects against various diseases of civilization

Frecska, E., Bokor, P., Winkelman, M. J. · Frontiers in Pharmacology (2016)

Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies

Dos Santos, R. G., Osório, F. L., Crippa, J. A. et al. · brazilian Journal of Psychiatry (2016)

130 cited
New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca

McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)

Serotonergic Hallucinogen-Induced Visual Perceptual Alterations

Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)

Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey

Schindler, E. A. D., Gottschalk, C. H., Weil, M. J. et al. · Journal of Psychoactive Drugs (2015)

91 cited
Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin

Lebedev, A. V., L€ Ovd En, M., Rosenthal, G. et al. · Human Brain Mapping (2015)

Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans

Rodríguez-Fornells, A., Ribeiro, S., Sanches, R. F. et al. · European Neuropsychopharmacology (2015)

Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction

Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

Halberstadt, A. L. · Behavioural Brain Research (2014)

Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes

Blough, B. E., Landavazo, A., Decker, A. M. et al. · Psychopharmacology (2014)

The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs

Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)

Ayahuasca and cancer treatment

Schenberg, E. E. · Sage Open Medicine (2013)

The induction of synaesthesia with chemical agents: a systematic review

Luke, D. P., Terhune, D. B. · Frontiers in Psychology (2013)

Broadband Cortical Desynchronization Underlies the Human Psychedelic State

Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)

427 cited
Psychedelics and mental health: a population study

Krebs, T. S., Johansen, P. ˚. Ø. · PLOS ONE (2013)

Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin

MacLean, K. A., Leoutsakos, J. S., Johnson, M. W. et al. · Journal for the Scientific Study of Religion (2012)

350 cited
Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects

Maclean, K. A., Johnson, M. W., Reissig, C. J. et al. · Psychopharmacology (2012)

Animal models of serotonergic psychedelics

Hanks, J. B., González-Maeso, J. · ACS Chemical Neuroscience (2012)

Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers

Johnson, M. W., Sewell, R. A., Griffiths, R. R. · Drug and Alcohol Dependence (2012)

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness

Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

Psilocybin occasioned mystical-type experiences:... — Research Summary & Context | Blossom